Department of Computer Engineering, SVKM'S NMIMS Mukesh Patel School of Technology Management and Engineering, Shirpur 425405, Maharashtra, India.
Department of Medical Education, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia.
Molecules. 2023 Feb 24;28(5):2130. doi: 10.3390/molecules28052130.
Mesenchymal stem cells (MSCs) have newly developed as a potential drug delivery system. MSC-based drug delivery systems (MSCs-DDS) have made significant strides in the treatment of several illnesses, as shown by a plethora of research. However, as this area of research rapidly develops, several issues with this delivery technique have emerged, most often as a result of its intrinsic limits. To increase the effectiveness and security of this system, several cutting-edge technologies are being developed concurrently. However, the advancement of MSC applicability in clinical practice is severely hampered by the absence of standardized methodologies for assessing cell safety, effectiveness, and biodistribution. In this work, the biodistribution and systemic safety of MSCs are highlighted as we assess the status of MSC-based cell therapy at this time. We also examine the underlying mechanisms of MSCs to better understand the risks of tumor initiation and propagation. Methods for MSC biodistribution are explored, as well as the pharmacokinetics and pharmacodynamics of cell therapies. We also highlight various promising technologies, such as nanotechnology, genome engineering technology, and biomimetic technology, to enhance MSC-DDS. For statistical analysis, we used analysis of variance (ANOVA), Kaplan Meier, and log-rank tests. In this work, we created a shared DDS medication distribution network using an extended enhanced optimization approach called enhanced particle swarm optimization (E-PSO). To identify the considerable untapped potential and highlight promising future research paths, we highlight the use of MSCs in gene delivery and medication, also membrane-coated MSC nanoparticles, for treatment and drug delivery.
间充质干细胞 (MSCs) 已新兴成为一种有潜力的药物输送系统。基于 MSC 的药物输送系统 (MSCs-DDS) 在治疗多种疾病方面取得了重大进展，这一点在大量研究中得到了证明。然而，随着该研究领域的快速发展，这种输送技术出现了一些问题，这些问题通常是由于其内在限制所致。为了提高该系统的有效性和安全性，同时正在开发几种前沿技术。然而，由于缺乏评估细胞安全性、有效性和生物分布的标准化方法，MSC 在临床实践中的应用进展严重受阻。在这项工作中，我们强调了 MSC 的生物分布和全身安全性，同时评估了目前基于 MSC 的细胞治疗的现状。我们还研究了 MSC 的潜在机制，以更好地了解肿瘤起始和传播的风险。探讨了 MSC 生物分布的方法，以及细胞治疗的药代动力学和药效学。我们还重点介绍了各种有前途的技术，如纳米技术、基因组工程技术和仿生技术，以增强 MSC-DDS。对于统计分析，我们使用方差分析 (ANOVA)、Kaplan Meier 和对数秩检验。在这项工作中，我们使用称为增强粒子群优化 (E-PSO) 的扩展增强优化方法创建了一个共享 DDS 药物分配网络。为了挖掘尚未开发的巨大潜力并突出有前途的未来研究方向，我们强调了 MSCs 在基因传递和药物治疗中的应用，以及膜包裹的 MSC 纳米颗粒，用于治疗和药物输送。
